中国TreatyWIPO
2022年2月11日

China Joins Two WIPO Treaties, the Hague System and the Marrakesh Treaty

Snow Pine painted by artist Evelyn Hui, mother of Eagle IP’s founder Dr. Jacqueline Lui

It has been two challenging years, yet there are many reasons to still have hope. We wish you a blessed Lunar New Year as we welcome the year of the Tiger.

We wanted to highlight a few new developments in China.

China has joined the Hague System for the International Registration of Industrial Designs, submitting its instrument of accession to the 1999 Geneva Act of the Hague Agreement on February 5, 2022. The Act will go into effect in China on May 5, 2022.

The Hague System provides a way for designers to file a single international design application to register up to 100 designs in up to 94 countries. This helps applicants save time and money on filing separately applications in each jurisdiction. Applicants don’t need to file a national or regional design application first. They can just directly file an international application in the Hague System in one language with one set of fees.

China joining the Hague System gives international designers the option to obtain design patent rights in China through the streamlined Hague System. Chinese designers likewise will have access to the Hague System and access to streamlined design registration in 90+ countries.

As part of this process, China has been updating its design patent laws to comply with Hague System requirements, most notably increasing design patent protection life from 10 years to 15 years in the newest 4th Amendment of the Patent Law. Full details will be available in May. Please note that Hong Kong and Macau are not included.

On the same day, China also signed onto the Marrakesh Treaty, a humanitarian treaty aimed at removing copyright barriers to providing visual impaired people access to published works. The Marrakesh Treaty was adopted on June 27, 2013 and is also administered by the World Intellectual Property Organization (WIPO). It currently has 84 contracting parties, including China, the US, and the European Union.

Eagle IP are experts in patent law and we offer a one-stop service for your global IP needs.

This article is for general informational purposes only and should not be considered legal advice or a legal opinion on a specific set of facts.

About the Authors

Jennifer Che, J.D. is Vice President and Principal at Eagle IP, a Boutique Patent Firm with offices in Hong Kong, Shenzhen, and Macau.

This article is for general informational purposes only and should not be considered legal advice or a legal opinion on a specific set of facts.

其他文章

Introducing the New USPTO Cancer Moonshot Expedited Examination Pilot Program

2023年1月10日
Starting from February 1, 2023, the USPTO will begin the new Cancer Moonshot Expedited Examination Pilot Program that advances out-of-turn applications that are directed to oncology or smoking cessation. This new program will replace the Cancer Immunotherapy Pilot Program that has been in place since 2016, and covers more technologies than only cancer immunotherapies. Applications […]

China Hands Down First Batch of Patent Linkage “Paragraph IV” Litigation Results

2022年6月30日
China has been implementing a plethora of new laws and measures that are particularly favorable to drug companies, such as patent term extension and patent linkage. Details of the new implementation measures for patent linkage (technically “early dispute resolution mechanisms for drug patents”) came into effect on July 4, 2021. At around the same time, […]

Do Promotional Marketing Materials Constitute an “Offer for Sale” under Chinese Patent Law? Bayer IP GmbH v. Nanjing Hang Seng Pharmaceutical

2023年12月12日
Bayer's blockbuster drug Rivaroxaban has seen its share of patent litigations in China, several of which are big enough to be listed as Top 10 IP cases or 50 Representative IP cases. We summarized an invalidation case back in 2020 where all of Bayer’s claims directed towards the compound were upheld. Recently, another Rivaroxaban case […]

China Patent Office (CNIPA) Releases More Details About Patent Term Adjustment (PTA) in the Draft Examination Guidelines

2021年10月19日
The new 4th Amendment of the Chinese Patent Law came into effect on June 1, 2021. Right before that date, the Chinese Patent Office (“CNIPA”) released some “Interim Measures” to give us a taste of what was to come, though they have yet to released the actual Implementation Rules. Two months later, CNIPA finally released […]

我们的过去活动

Top crossarrow-right